Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


CellCentric receives funding from Takeda Research Investment, Inc.


Press Release

2nd October 2007

CAMBRIDGE, UK

CellCentric, the biotechnology company unlocking epigenetic control mechanisms, has secured further financing to advance its epigenetic-related discovery and development activities. The funding will be used to increase target validation and small molecule development work, as well as to support CellCentric’s patent portfolio. Primary focus currently is on ubiquitin ligases and histone demethylases.

The first close of a two stage funding brings in over US$4.3m from Morningside Venture Investments Ltd., Takeda Research Investment, Inc. (TRI), the National Endowment for Sciences, Technology and the Arts (NESTA), and Providence Investment Company Ltd.


The funding achieved should take the company through to a point where CellCentric can achieve corporate collaborations and deals, both on its novel targets for cancer and epigenetic reprogramming screens.

Will West, CEO of CellCentric said “Achieving a significant corporate endorsement was a key goal for this year. The deal struck with Takeda’s corporate venture arm is just that. It would not have been possible without the commitment and passion for our novel business model from Morningside, NESTA and Providence, as well as the rest of the management team”.

Graeme Martin, President & CEO of TRI said “CellCentric is building a truly innovative business, consolidating the vast expertise and know-how of a global network of experts in epigenetics. We believe this is an emerging area of real significance in therapeutic drug discovery. Our investment is intended to help build a relationship that may lead to collaboration on multiple novel drug targets that CellCentric is validating.”

Note:

Takeda Research Investment, Inc. (TRI) is the corporate venture arm of Takeda Pharmaceutical Company Limited, a world-class pharmaceutical company and the largest in Japan. A wholly-owned subsidiary of Takeda America Holdings, Inc., TRI aims to encourage and support therapeutic innovation in biopharmaceutical companies and academic centres of excellence, through early stage capital investment and provision of access to the resources of a multinational pharmaceutical company.

Contact: Will West +44 1799 531 130 +44 7909 547 950
For further information on CellCentric and epigenetics, see www.cellcentric.com


Publisher Contact Information:

CellCentric Ltd.
+44 1799 531 130
Will.West@cellcentric.com

Company profile of CellCentric Ltd.
Past press releases of CellCentric Ltd..

Data


26,227
Tech investments
From our Online Data Service
16,943
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Oct 11N/AInternet services
Oct 11€1.1MKnowledge management
Oct 11N/AInternet services
Oct 11€13.0MBiotechnology
Oct 11N/AMedical devices
Oct 10€50.0MInternet services
Oct 10€23.0MOther Computers & Electronics

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.